Skip to main content
Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,473,000
-31,000 (-2.06%)
Last updated: Apr 29, 2026, 2:45 PM KST

Samsung Biologics Revenue

Samsung Biologics had revenue of 1.26T KRW in the quarter ending March 31, 2026, a decrease of -3.18%. This brings the company's revenue in the last twelve months to 4.81T, down -1.73% year-over-year. In the year 2025, Samsung Biologics had annual revenue of 4.56T with 30.31% growth.

Revenue (ttm)
4,814.00B
Revenue Growth
-1.73%
P/S Ratio
14.46
Revenue / Employee
926.66M
Employees
4,770
Market Cap
69.62T

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20254,556.97B1,059.83B30.31%
Dec 31, 20243,497.15B-197.44B-5.34%
Dec 31, 20233,694.59B693.29B23.10%
Dec 31, 20223,001.30B1,433.29B91.41%
Dec 31, 20211,568.01B403.23B34.62%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Celltrion 4,162.50B
ALTEOGEN 215.86B
Samsung Epis Holdings 1,510.14B
HLB Co., Ltd. 84.17B
SK Biopharmaceuticals 706.74B
LigaChem Biosciences 141.55B
Peptron 5.63B
Voronoi 7.51B
Revenue Rankings

Samsung Biologics News

More News